$PFSA

HRT FINANCIAL LP sold $3K of PFSA

HRT FINANCIAL LP sold 3,163 shares of Profusa, Inc. (PFSA) at $0.90 on 2026-08-14.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 18, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFSA
Neutral
medium confidence
Mentioned
$PFSA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

The newest fact is the reported open-market sale of 3,163 shares by a 10% owner at $0.9020, with holdings after the sale of 71,035 shares.

02

Market read

Traders may note incremental selling pressure, but there is no accompanying fundamental update in the text.

03

What to watch

The article does not state total position value change beyond share count, nor does it provide context for why the sale occurred.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA).

Company-level read

Ticker impact

$PFSANeutralMedium confidence
Context

Profusa, Inc. (PFSA) disclosed via Form 4 that HRT Financial LP sold 3,163 shares at $0.9020 on 2026-08-14.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine Form 4 transaction with no 10b5-1 plan and no accompanying company-specific news, guidance, or legal/operational change.

Market effects

No clear sector read-through from a single small Form 4 sale.

None indicated.

None indicated.

Counterpoint

A sale by a 10% owner can be liquidity-driven (taxes, diversification) and may not reflect bearish expectations.

Key entities

  • Profusa, Inc.

    Company whose shares were sold; subject of the Form 4 disclosure.

  • HRT Financial LP

    10% owner who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.